This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
February 23, 2017
Final Results from NICHE Phase III trial presented at the International Stroke Conference
February 23, 2017
Wilson Theraputics AB (publ) Year-end Report 2016
February 22, 2017
Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2016 Results Presentation and Webcast
February 22, 2017
Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today
February 21, 2017
GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy
February 20, 2017
Orexo Completes Bond Buyback Program
February 17, 2017
Publishing of Nexstim Plc 2016 Full Year Results
February 17, 2017
2016 ANNUAL RESULTS
February 16, 2017
Targovax ASA: Fourth quarter and full year 2016 results
February 13, 2017
Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.